Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Fingerprint

    Dive into the research topics of 'Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment'. Together they form a unique fingerprint.